Table 2.
Effects on organ function and weight
| Parameter | DLBS3233 (n=38)
|
Placebo (n=36)
|
P-valueb | ||
|---|---|---|---|---|---|
| Mean ± SD | P-valuea | Mean ± SD | P-valuea | ||
| ALT (U/L) at baseline | 29.8±16.8 | 30.2±18.0 | NS | ||
| Change at Week 12 | −7.0±11.7 | 0.001 | −4.5±14.1 | NS | NS |
| γ-GT (U/L) at baseline | 26.8±26.5 | 28.0±14.6 | NS | ||
| Change at Week 12 | −4.8±14.7 | NS | −3.3±14.0 | NS | NS |
| AP (U/L) at baseline | 69.2±18.8 | 72.50±19.36 | NS | ||
| Change at Week 12 | −6.3±12.8 | 0.001 | −2.44±10.51 | NS | NS |
| Creatinine (mmol/L) at baseline | 55.692±11.492 | 67.184±21.216 | 0.026 | ||
| Change at Week 12 | 3.536±10.608 | NS | 0.884±8.84 | NS | NS |
| SBP (mmHg) at baseline | 125.3±16.0 | 133.2±26.7 | NS | ||
| Change at Week 12 | −6.4±17.6 | 0.035 | −4.3±27.9 | NS | 0.013 |
| DBP (mmHg) at baseline | 81.3±10.4 | 85.3±14.2 | NS | ||
| Change at Week 12 | −4.7±12.0 | 0.026 | −3.3±15.3 | NS | 0.020 |
| Weight (kg) at baseline | 67.39±11.13 | 68.06±10.36 | NS | ||
| Change at Week 12 | −1.85±2.92 | <0.001 | −2.23±1.88 | <0.001 | NS |
Notes:
a
Within-group comparisons, statistical significance compared to baseline.
b
Between-group comparisons. NS, not statistically significant (P>0.05). Negative values are reduction from baseline, while positive values, increase from baseline.
Abbreviations: SD, standard deviation; ALT, alanine transaminase; γ-GT, γ-glutamyl transferase; AP, alkaline phosphatase; SBP, systolic blood pressure; DBP, diastolic blood pressure.